» Articles » PMID: 37952687

Mettl3/Ythdf2 Regulate Macrophage Inflammation and ROS Generation by Controlling Pyk2 MRNA Stability

Overview
Journal Immunol Lett
Date 2023 Nov 12
PMID 37952687
Authors
Affiliations
Soon will be listed here.
Abstract

As one of the most prevalent modifications on RNA, N6-methyladenosine (mA) has been recently found implicated in various pathological processes. Emerging studies have demonstrated the role of mA and its writer Mettl3 in fine-tuning the immune response, which now becomes a research hotspot owing to its potential therapeutic value. However, the results are inconsistent and even contradictory, suggesting that there might be multiple Mettl3 target genes involved in different pathways. To delve deeper into the function of Mettl3 in the cellular inflammatory response, we first conducted bioinformatics analysis using RNA-seq in Mettl3 ablation macrophages, and found that Mettl3 might attenuate LPS-induced proinflammatory pathways and reactive oxygen species (ROS) generation process. Mettl3 knockdown significantly increased the LPS-induced IL-6, TNF-α, NOXs (Nox1, Nox2, Ncf1, and Ncf2) expression, ROS generation, and the phosphorylation of MAPKs and AKT signaling. Combining the results of RNA-seq and mA mapping, we found that Pyk2 might be the target gene of Mettl3 affecting the inflammatory response. Mettl3 and Ythdf2 depletion increased the expression and mRNA stability of Pyk2, and RIP-PCR showed that Ythdf2 directly targeting Pyk2 was Mettl3 dependent. Moreover, the upregulated expression of TNF-α, IL-6, NOXs, ROS generation, and the phosphorylation of MAPKs and AKT signaling were downregulated by Pyk2 inhibitor in Mettl3 knockdown cells. All of these results suggest that Mettl3 regulates the mRNA stability and expression of Pyk2 in a Ythdf2-dependent way, which consequently triggers the activation of MAPKs and AKT signaling and upregulation of NOXs, thus promoting the generation of proinflammatory cytokines and ROS.

Citing Articles

The role of mA modification during macrophage metabolic reprogramming in human diseases and animal models.

Wang H, Xu P, Yin K, Wang S Front Immunol. 2025; 16:1521196.

PMID: 40066451 PMC: 11891544. DOI: 10.3389/fimmu.2025.1521196.


Mechanistic and therapeutic insights into the function of N6-methyladenosine in arthritic diseases.

Zhou X, Wu Y, Song Y, Wang B, Cai Y, Miao C Inflamm Res. 2025; 74(1):7.

PMID: 39762508 DOI: 10.1007/s00011-024-01969-3.


N6-methyladenosine (m6A) modification in inflammation: a bibliometric analysis and literature review.

Li Z, Lao Y, Yan R, Guan X, Bai Y, Li F PeerJ. 2024; 12:e18645.

PMID: 39686999 PMC: 11648684. DOI: 10.7717/peerj.18645.


The indispensability of methyltransferase-like 3 in the immune system: from maintaining homeostasis to driving function.

Zhang M, Gou Z, Qu Y, Su X Front Immunol. 2024; 15:1456891.

PMID: 39416774 PMC: 11479892. DOI: 10.3389/fimmu.2024.1456891.


Intestinal Epithelial Cell-specific Knockout of METTL3 Aggravates Intestinal Inflammation in CLP Mice by Weakening the Intestinal Barrier.

Shi H, Sun J, Sun Y, Wu J, Jiang G, Xu Z Curr Pharm Biotechnol. 2024; 26(1):80-91.

PMID: 38482615 DOI: 10.2174/0113892010271970240202054245.